The safety of tibolone in epithelial ovarian cancer patients

Maturitas

Volumn 55, Issue 2, 2006, Pages 156-161

  Lee, Kwang Beom ^a   Lee, Jong Min ^a   Yoon, Jung Hye ^a   Park, Chan Yong ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Ovarian cancer patients; Survival; Tibolone

Indexed keywords

TIBOLONE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; HUMAN; KOREA; MAJOR CLINICAL STUDY; OVARY CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CLIMACTERIC; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NORPREGNENES; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748147326     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.01.010     Document Type: Article

References (16)

1. 2002 Annual report of the Korea central cancer registry (2002.1-2002.12). Republic of Korea: Korea Central Cancer Registry, Ministry of Health and Welfare; 2003.
2. Pecorelli S., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. Annual report on the results of treatment of gynecological cancer, vol 23. International Federation of Gynecology and Obstetrics. J Epidemiol Biostat 3 (1998) 75-102
3. Berek J.S., and Hacker N.F. Epithelial ovarian cancer-practical gynecologic oncology. 3rd ed. (2005), Lippincott Williams & Wilkins, Philadelphia
4. Trimble E.L., Kosary C.A., Cornelison T.L., et al. Improved survival for women ovarian cancer. Proc Soc Gynecol Oncol (1999) (Abstract 136)
5. Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 25 (1986) 383
6. Eeles R.A., Tan S., Wiltshaw E., et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302 (1991) 259-262
7. Guidozzi F., and Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 86 (1999) 1013-1018
8. Urisc-Vrscaj M., Bebar S., and Primic Zakelij M. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 8 (2001) 70-75
9. Whittemore A.S., Harris R., and Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancer in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136 (1992) 1184-1203
10. Grag P.P., Kerlikowske K., Subak L., et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92 (1998) 472-479
11. Hunt K., Vessey M., and McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynecol 97 (1990) 1080-1086
12. Modelska K., and Cummings S. Tibolone for postmenopausal women: systemic review of randomized trials. J Clin Endocrinol Metab 7 (1993) 183-202
13. Gruber C.J., Tschugguel W., Schneeberger C., et al. Production and actions of estrogens. N Engl J Med 31 (2002) 340-352
14. Colacurci N., Mele D., De Franciscis P., et al. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 80 (1998) 235-238
15. Kloosterboer H.J., Schoonen W.G., Deckers G.H., et al. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 49 (1994) 311-318
16. Gompel A., Siromachkova M., Lombet A., et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer 36 (2000) 76-77